T-Cells

Cell and gene therapies
#Cell and gene therapy #Macrophages #Solid tumours #T-Cells

Laverock reports positive data from oncology programmes 

Laverock Therapeutics has reported in vivo functional milestones across its T-cell and macrophage oncology programmes as it advances its lead programme towards clinic.  Data from ovarian cancer models, presented at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting in May, demonstrated the company’s… Read More

#Cancer Research #News

#Biotechnology #Cancer research #Clinical research #Innovation passport #MHRA #Solid tumours #T-Cells

Uveal melanoma drug granted MHRA Innovation Passport 

iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, has been awarded the innovative medicine designation, the Innovation Passport, for roginolisib, for the treatment of metastatic uveal melanoma by the Medicines & Healthcare products Regulatory Agency (MHRA).  Roginolisib is a first-in-class, non-ATP-competitive,… Read More

#News

Haematology
#Biotechnology #Cancer research #Clinical research #Solid tumours #T-Cells

Research reveals the unique biological features of roginolisib 

iOnctura, a clinical stage biotechnology company developing cancer therapies, has published non-clinical research on roginolisib in the AACR journal Cancer Research Communications. Roginolisib is a first-in-class, non-ATP-competitive, allosteric modulator of PI3Kd which prevents tumour proliferation and breaks immune tolerance in patients with solid and haematological… Read More

#Cancer Research #News

Myeloma cells
#Antibody #Cancer research #Europe #European Medicines Agency #Janssen #Marketing approval authorisation #Myeloma #T-Cells

Janssen seeks European approval for multiple myeloma drug

Janssen has submitted a marketing authorisation application (MAA) seeking approval of talquetamab in Europe for the treatment of patients with relapsed or refractory multiple myeloma (RRMM).   Talquetamab is an investigational, off-the-shelf, bispecific T-cell engager antibody targeting both GPRC5D, a novel drug target that is on some normal… Read More

#Cancer Research #News

T cells attacking cancer
#Cancer #Cancer immunotherapy #Cell and gene therapy #Cell therapy #HER2 #Immunotherapy #Oncology #Precision medicine #T-Cells #Tumours

Positive interim data for cell therapy in solid tumours

Triumvira Immunologics has revealed positive clinical data from its ongoing TACTIC‑2 Phase I/II trial of TAC01-HER2 in patients with human epidermal growth factor receptor 2 (HER2) positive solid tumours.  These interim data demonstrate that TAC01-HER2 is well-tolerated and clinical activity was observed in the two higher dosing cohorts,… Read More

#Cancer Research #News

T cells attacking cancer
#Cancer #Cancer immunotherapy #Cancer research #Cancer vaccine #National Institute of Allergy and Infectious Diseases #Oncology #T-Cells

Experimental cancer vaccine shows promise in animal studies 

An experimental therapeutic cancer vaccine induced immune system responses that led to significant tumour regression in mice, according to investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.    The researchers found that intravenous (IV) administration of the vaccine… Read More

#Cancer Research #News

#Immunology #In vivo #Mouse models #T-Cells

Read the Top Five Benefits of a Cloud ELN

As experimental data becomes bigger and more complex, scientists are challenged to make discoveries faster, consistently document and analyse their work, and easily collaborate across an organisation and with external partners. Electronic lab notebooks (ELN) provide access to all collaborators 24/7, wherever they are and whether they are employees or… Read More

#Intelligence #Resources

Lab mouse
#Immunology #Mouse models #T-Cells

Whitepaper: The benefits of a mouse platform humanised with PBMCs

Mouse models with human immune cell engraftment provide platforms to evaluate compounds to treat a variety of human diseases. Humanised PBMC (hu-PBMC) mice feature quick engraftment of adult peripheral blood mononuclear cells and enable short-term studies requiring mature human T cells. Hu-PBMC mice are used as in vivo models to… Read More

#News

#Immunology #In vivo #Mouse models #T-Cells

The latest MHC class I & II deficient in vivo platform humanised with PBMCs

This whitepaper, brought to you by The Jackson Laboratory will teach: The benefits of the JAX NSGTM-MHC I/II KO mouse platform humanised with pre-characterised PBMCs How this platform can support a wide range of immunological studies, especially those containing T cells responses The versatility of this platform to various research disciplines… Read More

#Intelligence #Resources

#Cancer research #Immunotherapy #Oncology #T-Cells

Blocking key enzyme boosts anti-cancer T-cell responses

A study led by LSU Health New Orleans cancer researchers describes a novel therapeutic strategy to overcome tumour-induced immunosuppression. For the first time, the research team identified a critical immunosuppressive pathway and a promising approach to intervene, protecting the ability of T-cells to attack cancer cells. Results are published in… Read More

#Cancer Research #Editor's Choice #News

#Acquisition #Collaboration #Oncology #T-Cells #Therapeutics

Takeover plan looks to develop T cell engager therapies 

Tokyo-based Takeda Pharmaceutical has optioned to acquire Adaptate Biotherapeutics, a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells.   The acquisition   Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programmes. Adaptate’s γδ T cell engagers are… Read More

#News

RNA
#CAR-T #Immunology / Virology & Vaccines #mRNA #T-Cells

Vaccine-like mRNA injection can be used to make CAR-T cells 

A study from researchers in the Perelman School of Medicine at the University of Pennsylvania has shown that an experimental immunotherapy can temporarily reprogramme patients’ immune cells to attack a specific target via only a single injection of mRNA, similar to the mRNA-based Covid-19 vaccines.  Context  The researchers, whose… Read More

#News

#Covid booster #Covid-19 #Immunology / Virology & Vaccines #Omicron #RNA #T-Cells

Early data for multivariant Covid-19 vaccine booster shows promise  

The first results of an early trial of a multivariant Covid-19 vaccine booster, launched in Manchester in September 2021, has shown it is driving a comprehensive immune response.  The results  US-based biotechnology company Gritstone bio, in collaboration with The University of Manchester and Manchester University… Read More

#Covid-19 #News

#Immuno-oncology #Immunotherapy #T-Cells

The evolving immuno-oncology landscape 

Dr Ian Walters, Chief Executive Officer and Director of Portage Biotech, shares how to find the path of least resistance through the immuno-oncology landscape.  Our bodies are naturally trained to identify and remove abnormal cells, including those that are cancerous. Under normal circumstances, a person’s immune system detects proteins on the surface of cancer cells and targets them for elimination. The… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News #Opinion

#Covid-19 #Research study #T-Cells

How is Japan keeping Covid-19 cases so low? 

Research by the Riken Institute in Tokyo, published in the British journal Communications Biology, offers an explanation for Japan’s success in tackling the Covid-19 pandemic when compared with other countries. The research is a piece of the puzzle of why there remains relatively low rates of death and serious… Read More

#Covid-19 #News #Trending News